mRNA Synthesis Raw Materials Market Size & Growth Forecast 2026–2035, By Segments (Application, End-use, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
mRNA Synthesis Raw Materials Market size stood at USD 1.8 Billion in 2025 and is predicted to grow at a 2.9% CAGR from 2026 to 2035, exceeding USD 2.4 Billion by 2035. The industry revenue for 2026 is estimated at USD 1.84 billion.
Get more details on this report
Request Free Sample ReportmRNA Synthesis Raw Materials Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 38.16% of the market in 2025, supported by advanced biopharmaceutical manufacturing, integrated supplier networks, and strong demand from clinical and commercial mRNA programs.
- Asia Pacific is projected to expand at a 3.31% CAGR as biomanufacturing capacity grows, biotechnology infrastructure improves, and organizations increase mRNA development and production activities.
Segment Momentum
- Vaccine Production accounted for a 79.76% share in 2025, driven by large-scale manufacturing, standardized sourcing practices, recurring procurement, and stringent quality requirements for high-purity raw materials.
- CROs & CMOs are expanding fastest as more developers outsource mRNA development and manufacturing to gain technical expertise, flexibility, and production capacity without significant in-house infrastructure investment.
Market Expansion Drivers
- Expanding mRNA vaccine and therapeutic pipeline driving reagent consumption growth.
- GMP-compliant biomanufacturing expansion increasing demand for high-purity synthesis materials.
- Supply chain localization efforts strengthening regional sourcing of critical biopharma raw materials.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Leading players in the mRNA synthesis raw materials market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Maravai LifeSciences Holdings, Inc. (United States), New England Biolabs, Inc. (United States), Jena Bioscience GmbH (Germany), Hongene Biotech Corporation (China), Yeasen Biotechnology (Shanghai) Co., Ltd. (China), Danaher Corporation (United States), TriLink BioTechnologies LLC (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As more candidates move from discovery into preclinical and clinical development, the mRNA synthesis raw materials market sees rising pull-through demand for nucleotides, capping reagents, enzymes, plasmid templates, and purification inputs used repeatedly in formulation optimization, analytical testing, process development, and batch production. This pipeline expansion changes buying behavior from small, intermittent research purchases to larger and more structured procurement programs, because developers need consistent raw material availability to support multiple parallel programs and rapid iteration cycles. The result is stronger demand visibility for suppliers serving the mRNA synthesis raw materials market, particularly where materials must perform reliably across scale-up stages without requiring major process rework.
GMP-compliant biomanufacturing expansion increasing demand for high-purity synthesis materials
The build-out of GMP production capacity is shifting procurement toward raw materials that can meet tighter quality documentation, traceability, impurity control, and lot-to-lot consistency requirements. In the mRNA synthesis raw materials market, this elevates demand for highly characterized enzymes, nucleotides, lipids-related intermediates, and other synthesis inputs that can be integrated into validated manufacturing workflows and regulatory filings. Buyers are not simply increasing volumes; they are narrowing supplier pools in favor of vendors able to support qualification, audit readiness, and change-control expectations, which supports market expansion for premium-grade materials and strengthens the position of specialized suppliers.
Supply chain localization efforts strengthening regional sourcing of critical biopharma raw materials
Efforts to reduce dependence on distant or concentrated supply bases are reshaping procurement strategies in the mRNA synthesis raw materials market toward regional manufacturing footprints and dual-source arrangements for critical inputs. Biopharma companies and CDMOs are placing greater weight on lead-time reliability, geopolitical resilience, and continuity planning, especially for materials that can delay development or commercial production if supply is interrupted. This is increasing market penetration for regional suppliers that can offer localized inventory, faster technical coordination, and closer alignment with domestic regulatory and quality expectations, while also prompting established global vendors to expand local capacity and distribution networks.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding mRNA vaccine and therapeutic pipeline driving reagent consumption growth | 2.60% | High | North America, Europe | High | Mid Term |
| GMP-compliant biomanufacturing expansion increasing demand for high-purity synthesis materials | 2.30% | High | North America, Asia Pacific, Europe | High | Mid Term |
| Supply chain localization efforts strengthening regional sourcing of critical biopharma raw materials | 1.70% | Moderate | North America, Europe, Asia Pacific | Medium | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 38.16% share of the mRNA synthesis raw materials market in 2025, bolstered by its established biopharmaceutical manufacturing base, strong concentration of advanced research activity, and mature procurement networks for high-purity inputs. The region’s leadership is reinforced by the close linkage between raw material suppliers, CDMOs, biotech developers, and academic research centers, which supports consistent demand for nucleotides, enzymes, capping reagents, and related production-grade materials. In practice, this integrated operating environment helps shorten sourcing cycles, sustain quality standards, and support repeat purchasing across both clinical and commercial mRNA programs.
Asia Pacific is projected to expand at a 3.31% CAGR over the forecast period, with growth in the mRNA synthesis raw materials market being impelled by expanding biomanufacturing capacity and a broader regional push to strengthen local supply chains for advanced therapeutics. Demand is accelerating as more organizations in the region move from research-scale activity toward pilot and production-scale mRNA development, increasing the need for reliable raw material sourcing and process support. The market is also benefiting from rising investment in biotechnology infrastructure, which is improving the region’s ability to absorb higher-value material inputs and support more regular purchasing across development pipelines.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality Manufacturing BaseGermany emphasizes high-purity raw materials that support regulated mRNA manufacturing and pharmaceutical innovation. Suppliers focus on scalable production, stringent quality control, and close collaboration with biotechnology companies developing next-generation RNA-based therapies.
France 🇫🇷
Research Collaboration FocusFrance supports the mRNA synthesis raw materials market through collaborative pharmaceutical research and biotechnology development initiatives. Material suppliers increasingly provide specialized reagents and technical support that improve manufacturing efficiency and product consistency.
Italy 🇮🇹
Specialized Reagent SupplyItaly strengthens the mRNA synthesis raw materials market by expanding access to specialized laboratory reagents and pharmaceutical manufacturing inputs. Companies increasingly seek dependable suppliers capable of supporting flexible production requirements and regulatory compliance.
Japan 🇯🇵
Precision Material StandardsJapan prioritizes reliable and highly consistent raw materials for mRNA synthesis across research and clinical applications. Domestic demand encourages suppliers to enhance manufacturing precision, analytical validation, and long-term supply continuity for pharmaceutical developers.
South Korea 🇰🇷
Biotech Capacity SupportSouth Korea is expanding demand for mRNA synthesis raw materials through investments in biotechnology manufacturing and contract development services. Suppliers increasingly align production capabilities with scalable RNA platforms and internationally accepted quality requirements.
United States 🇺🇸
Bioprocess Supply ExpansionThe U.S. mRNA synthesis raw materials market is driven by continued investment in biopharmaceutical manufacturing and advanced therapeutics. Companies prioritize secure sourcing of nucleotides, enzymes, and specialized reagents while strengthening domestic supply resilience for research and commercial production.
Segment Leadership and Growth Trends
mRNA Synthesis Raw Materials Market Share (%), Application, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportVaccine Production held the dominant position in the mRNA synthesis raw materials market in 2025, accounting for a 79.76% share. This dominance is sustained by the established scale of mRNA vaccine manufacturing, where raw material procurement is closely tied to validated production workflows, stringent quality requirements, and recurring demand for high-purity inputs. The vaccine production segment continues to command the largest share because manufacturers typically operate with larger batch volumes and more standardized sourcing needs than other application areas in the mRNA synthesis raw materials market.
Therapeutics Production is the fastest-growing application in the mRNA synthesis raw materials market as development activity expands beyond vaccines into broader mRNA-based treatment programs. Growth is being aided by the rising need for specialized raw materials that can meet more diverse formulation, process development, and clinical manufacturing requirements. Compared with vaccine production, therapeutics production is gaining momentum from a widening pipeline base, which is increasing demand for flexible and application-specific material inputs across development and early commercialization stages.
End-use Segment Analysis: Biopharmaceutical & Pharmaceutical Companies (Largest Segment) vs CROs & CMOs (Fastest-Growing Segment)
By end use, Biopharmaceutical & Pharmaceutical Companies represented the largest portion of the mRNA synthesis raw materials market in 2025, with a 52.18% share. Their leadership reflects direct control over mRNA research, process development, clinical advancement, and commercial manufacturing planning, all of which create steady purchasing demand for critical raw materials. This segment retains the largest share because internal development programs and established production responsibilities keep procurement concentrated within companies managing core product pipelines and quality oversight.
CROs & CMOs are emerging as the fastest-growing end-use segment in the mRNA synthesis raw materials market as outsourcing becomes more practical for developers seeking speed, technical capacity, and manufacturing flexibility. Their momentum is tied to the growing number of mRNA programs that require external support for development and production without heavy in-house infrastructure investment. Relative to biopharmaceutical and pharmaceutical companies, CROs & CMOs are benefiting from rising outsourced project volumes, which is translating into faster expansion in raw material consumption.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Vaccine Production, Therapeutics Production, Others | Vaccine Production | Therapeutics Production |
| End-use | Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes | Biopharmaceutical & Pharmaceutical Companies | CROs & CMOs |
| Type | Capping Agents, Nucleotides, Plasmid DNA, Enzymes, Others | Nucleotides | Capping Agents |
Competitive Landscape and Market Positioning
1. Merck KGaA (Germany)
2. Thermo Fisher Scientific Inc. (United States)
3. F. Hoffmann-La Roche Ltd. (Switzerland)
4. Maravai LifeSciences Holdings Inc. (United States)
5. New England Biolabs Inc. (United States)
6. Jena Bioscience GmbH (Germany)
7. Hongene Biotech Corporation (China)
8. Yeasen Biotechnology (Shanghai) Co. Ltd. (China)
9. Danaher Corporation (United States)
10. TriLink BioTechnologies LLC (United States)
Rising biopharmaceutical innovation is driving strong momentum in the mRNA synthesis raw materials market. The mRNA synthesis raw materials market is evolving through advanced molecular techniques that enhance synthesis accuracy and scalability. Continuous research focus is enabling more stable and efficient raw material development for therapeutic applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Moderna | Nov-25 | Moderna invested USD 140 million to complete its domestic mRNA manufacturing network in the United States. The investment strengthens local production capacity and increases demand for mRNA synthesis raw materials, reinforcing supply chain localization and supporting scalable mRNA therapeutic manufacturing infrastructure. |
| Syvento Biotech | Nov-24 | Syvento Biotech and Cytiva inaugurated a FlexFactory facility in Poland to accelerate mRNA therapy development. The modular, automated platform enhances manufacturing scalability and digital integration, strengthening regional capacity for mRNA production and supporting faster therapeutic development timelines. |
| Hongene Biotech Corporation | Sep-24 | Hongene Biotech Corporation and ReciBioPharm formed a strategic partnership integrating sgRNA synthesis technology into a unified gene editing manufacturing platform. The collaboration enables end-to-end capabilities including plasmid, mRNA, sgRNA, and LNP production, improving process integration and reducing manufacturing fragmentation. |
| Merck KGaA | Feb-22 | Merck KGaA acquired Exelead, a U.S.-based CDMO, to strengthen its mRNA vaccine and therapeutic development capabilities. The acquisition supports long-term expansion of lipid and mRNA manufacturing capacity and reinforces Merck’s position in advanced nucleic acid-based therapeutics. |
| BioSpring | Jul-25 | BioSpring committed several hundred million euros to build a ton-scale RNA manufacturing facility in Germany. The investment significantly expands European RNA raw material production capacity and strengthens regional supply resilience for mRNA-based therapeutics and vaccines. |
| TriLink BioTechnologies | May-25 | TriLink BioTechnologies and the International Vaccine Institute signed an MoU to co-develop mRNA vaccines for global access. The collaboration supports expanded mRNA production initiatives and reinforces demand for synthesis raw materials within equitable vaccine development programs. |
| GenScript | May-24 | GenScript launched a self-amplifying RNA synthesis service for therapeutic applications. The offering enhances production capabilities for vaccines and gene therapies, strengthening its position in the expanding RNA synthesis and advanced biologics manufacturing ecosystem. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
mRNA Synthesis Raw Materials Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
mRNA Synthesis Raw Materials Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the mRNA synthesis raw materials market?
How is the mRNA synthesis raw materials industry size expected to evolve during the forecast period?
How is the expanding mRNA vaccine and therapeutics pipeline reshaping procurement and consumption of synthesis raw materials?
How are GMP biomanufacturing requirements influencing supplier selection and material specifications in the mRNA synthesis raw materials market?
Why does Vaccine Production lead the mRNA synthesis raw materials market?
Why are CROs & CMOs the fastest-growing end users in the mRNA synthesis raw materials market?
Why is North America the leading market for mRNA synthesis raw materials?
Which region is expected to grow fastest in the mRNA synthesis raw materials market?
Who are the leading players in the mRNA synthesis raw materials landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization